Dominant negative mutant KRP protein protection of active cyclin-CDK complex inhibition by wild-type KRP
US9637754B2 · kind B2 · utility
1Cited by
11References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 15, 2014 |
| Grant date | May 2, 2017 |
| Priority date | — |
| Expiry date | Nov 11, 2034 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A40/146
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Disclosed are mutant CDK inhibitor (CKI) polypeptides having dominant negative antagonist activity against wild-type CKI proteins, as well as related compositions, including nucleic acids and vectors encoding the mutant CKI polypeptides and transformed host cells and transgenic plants comprising such nucleic acids and vectors. Also disclosed are related methods for using the mutant proteins to modulate cell division in cells, particularly plant cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.